Abevmy (bevacizumab)

pCPA File Number: 21437
Negotiation Status:
Active Negotiation
Indication(s):
Metastatic colorectal cancer (mCRC), locally advanced, metastatic or recurrent non-small cell lung Cancer (NSCLC), platinum-resistant recurrent epithelial ovarian, fallopian tube and primary peritoneal cancer, and glioblastoma
Sponsor/Manufacturer:
BGP Pharma ULC
CADTH Project Number:
Not Applicable
pCPA Engagement Letter Issued:
Negotiation Process Concluded:
Not Applicable